Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MC5R | P33032 | 16/20 | 0.53 |
| ▸ | MC4R | P32245 | 6/20 | 0.53 |
| ▸ | MC3R | P41968 | 6/20 | 0.53 |
| ▸ | MC1R | Q01726 | 2/20 | 0.43 |
| ▸ | NAMPT | P43490 | 1/20 | 0.35 |
| ▸ | CTNNB1 | P35222 | 2/20 | 0.35 |
| ▸ | TCF7L2 | Q9NQB0 | 2/20 | 0.35 |
| ▸ | USP28 | Q96RU2 | 1/20 | 0.35 |
| ▸ | USP25 | Q9UHP3 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2742682 | 1.00 | MC5R (0.53) | MC5RMC4RMC3RMC1RNAMPT | |
| SCHEMBL4050294 | 0.94 | MC5R (0.53) | MC5RMC4RMC3RMC1RNAMPT | |
| SCHEMBL4050286 | 0.94 | MC5R (0.53) | MC5RMC4RMC3RMC1RNAMPT | |
| SCHEMBL4050292 | 0.94 | MC5R (0.53) | MC5RMC4RMC3RMC1RNAMPT | |
| SCHEMBL4045951 | 0.93 | MC5R (0.54) | MC5RMC4RMC3RMC1RNAMPT | |
| SCHEMBL4045953 | 0.93 | MC5R (0.54) | MC5RMC4RMC3RMC1RNAMPT | |
| SCHEMBL4045949 | 0.93 | MC5R (0.54) | MC5RMC4RMC3RMC1RNAMPT | |
| SCHEMBL4038130 | 0.93 | MC5R (0.52) | MC5RMC4RMC3RMC1RNAMPT | |
| SCHEMBL4038136 | 0.93 | MC5R (0.52) | MC5RMC4RMC3RMC1RNAMPT | |
| SCHEMBL4038137 | 0.93 | MC5R (0.52) | MC5RMC4RMC3RMC1RNAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8841290-B2 | Substituted tetrahydronaphthalenes, method for the production thereof, and use thereof as drugs | SANOFI (FR) | 2014-09-23 | — | — | US | disclosed |
| EP-2240474-B1 | CYCLIC PYRIDYL-N-(1,3,4)-THIADIAZOL-2-YL-BENZENE SULFONAMIDES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | SANOFI SA (FR) | 2012-03-14 | — | — | EP | disclosed |
| US-20120015936-A1 | SUBSTITUTED TETRAHYDRONAPHTHALENES, METHOD FOR THE PRODUCTION THEREOF, AND USE THEREOF AS DRUGS | SANOFI (FR) | 2012-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015936-A1 | SUBSTITUTED TETRAHYDRONAPHTHALENES, METHOD FOR THE PRODUCTION THEREOF, AND USE THEREOF AS DRUGS | PAH, MCHR1, DHPS | MC5R 40/4885MC4R 51/4885MC3R 50/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.